Is Space Biotech Building Its Apps Before Its Operating System? (Hyper Frame)

UF Innovate | Accelerate resident client Aloft Biotechnologies targets microgravity fluid management layer; industry orbital experiments are generally scale-limited and focused on pharma applications instead of the scalable outputs of biology; hardware stack development lags application investment.

Aloft Biotechnologies has publicly disclosed Float-Layer technology, a cell culture bioreactor architecture designed to address the fluid containment, gas exchange, and mechanical stability challenges specific to microgravity environments (as described in the company’s 2025 accelerator materials.)